This legislation aims to promote the production of generic drugs and biosimilars in the United States by providing financial incentives for domestic manufacturing. By encouraging companies to produce these essential medications locally, the bill seeks to enhance their availability and potentially reduce healthcare costs for consumers. The bill introduces two main tax credits: a production credit and an investment credit.